Matching articles for "Abrysvo"
In Brief: RSV Vaccine (Arexvy) for Ages 50-59
The Medical Letter on Drugs and Therapeutics • July 22, 2024; (Issue 1707)
The recombinant respiratory syncytial virus (RSV)
vaccine Arexvy (GSK) has now received FDA
approval for use in adults 50-59 years old who
are at increased risk for lower respiratory tract
disease (LRTD)...
The recombinant respiratory syncytial virus (RSV)
vaccine Arexvy (GSK) has now received FDA
approval for use in adults 50-59 years old who
are at increased risk for lower respiratory tract
disease (LRTD) caused by RSV. It was previously
approved only for adults ≥60 years old. Two other
RSV vaccines have received FDA approval: Abrysvo,
a recombinant vaccine that is licensed for use in
adults ≥60 years old and in pregnant women at
32-36 weeks' gestation to prevent RSV-associated
LRTD in their infants, and mResvia, an mRNA vaccine
recently licensed for use in adults ≥60 years old that
will be available for the 2024-25 RSV season.
Two Vaccines (Arexvy and Abrysvo) for Prevention of RSV Disease
The Medical Letter on Drugs and Therapeutics • October 2, 2023; (Issue 1686)
Two recombinant vaccines, Arexvy (GSK) and
Abrysvo (Pfizer), have been approved by the FDA for
prevention of lower respiratory tract disease (LRTD)
caused by respiratory syncytial virus (RSV) in...
Two recombinant vaccines, Arexvy (GSK) and
Abrysvo (Pfizer), have been approved by the FDA for
prevention of lower respiratory tract disease (LRTD)
caused by respiratory syncytial virus (RSV) in adults
≥60 years old. They are the first RSV vaccines to be
approved in the US. Abrysvo is also approved for
use in pregnant women at 32-36 weeks' gestation
to prevent LRTD caused by RSV in their infants from
birth through 6 months of age.
Nirsevimab (Beyfortus) for Prevention of Severe RSV Disease in Young Children
The Medical Letter on Drugs and Therapeutics • September 18, 2023; (Issue 1685)
The FDA has approved nirsevimab-alip (Beyfortus –
AstraZeneca/Sanofi), a long-acting monoclonal
antibody, for the prevention of respiratory syncytial
virus (RSV) lower respiratory tract disease...
The FDA has approved nirsevimab-alip (Beyfortus –
AstraZeneca/Sanofi), a long-acting monoclonal
antibody, for the prevention of respiratory syncytial
virus (RSV) lower respiratory tract disease in
neonates and infants born during or entering their
first RSV season, and in children ≤24 months old who
are at increased risk for severe RSV disease through
their second RSV season. Nirsevimab is the first drug
to be approved for protection of all infants during
their first RSV season.